Multiple Myeloma clinical trials in Vermont

2 actively recruiting multiple myeloma trials at 2 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed 2026-05-25

Phase 3 Recruiting Network

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT04566328

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont
White River Junction Veteran Administration Medical Center — White River Junction, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06179888

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25